Evidence map›Paper›PMID 31568936›Full record

ArticleDrug and alcohol dependence2019

Medical use, non-medical use and use disorders of benzodiazepines and prescription opioids in adults: Differences by insurance status.

Vítor Soares Tardelli, Thiago Marques Fidalgo, Julian Santaella, Silvia S Martins

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. De-prescribing opioids among Medicaid patients with long-term opioid use.Journal of substance use and addiction treatment · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Vítor Soares TardelliDepartamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil; Department of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: vstardelli@unifesp.br.
Thiago Marques FidalgoDepartamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. Electronic address: marquesfidalgo@yahoo.com.
Julian SantaellaDepartment of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: julian.santaella@gmail.com.
Silvia S MartinsDepartment of Epidemiology - Columbia University Mailman School of Public Health, New York, NY, United States. Electronic address: ssm2183@columbia.edu.
Columbia University · USUniversidade Federal de São Paulo · BR

Funding

State medical marijuana laws and NSDUH marijuana use and consequences since 2004R01DA037866 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARTINS, SILVIA SABOIA · 2014 to 2018
$2.3M
NIDA NIH HHS R01 DA037866
6 · The paper itself

Abstract

objectivesTo report and analyze prevalence's of Benzodiazepines (BZDs) and Prescription Opioids (POs) use by insurance status and to investigate associations between insurance status and BZDs, POs and concurrent medical/non-medical use and use disorders.

methodsThis study included 81,133 adults ages 18 and older from 2015 and 2016 National Survey on Drug Use and Health. Participants' self-reported past- year medical use, non-medical use and use disorders of BZDs and POs were assessed, along with their insurance status (Private/Military, Medicare, Medicaid, and Uninsured) and demographic characteristics.

resultsIn 2015-2016, 12.6% of adults reported using BZDs and 36.9% reported using POs in the past year. Among adults, 8.3% reported past-year use of both BZDs and POs; also, 1.9% and 3.8% reported non-medical use of BZDs and POs, respectively, and 0.9% reported non-medical use of both BZDs and POs. Medicaid-covered respondents had higher risk of BZDs (aRRR = 1.59, 95%CI = [1.45, 1.74]), POs (aRRR = 1.66, 95%CI = [1.54, 1.79]) and concurrent past-year medical use (aRRR = 2.11, 95%CI = [1.87, 2.38]), higher risk of BZDs non-medical use (aRRR = 1.40, 95%CI = [1.17, 1.68]) and BZD Use Disorders (aRRR = 2.60, 95%CI = [1.82, 3.72]), POs non-medical use (aRRR = 1.67, 95%CI = [1.45, 1.92]), PO use Disorders (aRRR = 4.12, 95%CI = [3.33, 5.11]) and concurrent non-medical use (aRRR = 1.52, 95%CI = [1.20, 1.92]) and Use Disorders (aRRR = 3.68, 95%CI = [1.93, 6.78]), compared to those with private insurance.

conclusionsFuture health policies should focus on reducing individual and co-prescription of BZDs and POs and providing different strategies of pain management.

Indexed as

AdolescentAdultAnalgesics, OpioidBenzodiazepinesDrug UtilizationFemaleHumansInsurance CoverageMaleMiddle AgedSelf MedicationSubstance-Related DisordersUnited StatesAnalgesics, OpioidBenzodiazepinesBenzodiazepinesEpidemiologyInsuranceOpioidsPrescription opioids

Identifiers

PMID31568936
PMCPMC6938257
OpenAlexW2973381736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.